Biotech: Page


  • Vertex
    Image attribution tooltip
    Permission granted by Vertex
    Image attribution tooltip

    Vertex, ahead of FDA decision, calms fears surrounding kidney drug

    On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future. 

    By • Nov. 3, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    UniQure gets an FDA decision date; Teva scraps brain drug study

    The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback. 

    By BioPharma Dive staff • Nov. 3, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • A Chapter 11 bankruptcy court document, with a pen under the word "bankruptcy."
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Karyopharm, deep in debt, to sell itself in bankruptcy

    The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.

    By • Nov. 2, 2026
  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience

    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.

    By • Nov. 2, 2026
  • single science glass flask with double exposure scientist holding tube in chemistry blue laboratory with stock market information background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: ESMO’s winners and losers

    The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.

    By • Oct. 30, 2026
  • A man in a blue suit stands for a photo.
    Image attribution tooltip
    Permission granted by Actio Bio
    Image attribution tooltip
    Startup launches

    With Setara, the team behind Actio opens its second act

    The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.

    By • Oct. 30, 2026
  • A person points to the start of a successful business on a blue stock market graph.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s

    The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.

    By • Oct. 29, 2026
  • Three people work in Empress Therapeutics' lab.
    Image attribution tooltip
    Permission granted by Empress Therapeutics
    Image attribution tooltip
    Startup launches

    Flagship blends three biotech startups to form Etcelera

    Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.

    By • Oct. 29, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Lilly shuffles business structure; Novartis writes off part of Avidity deal

    Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.

    By BioPharma Dive staff • Oct. 28, 2026
  • Spermatozoon is injected into an ovum with help of microneedle and holding pipette underneath a microscope
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ferring to acquire next-gen IVF startup Gameto for up to $1.4B

    The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.

    By • Updated Oct. 28, 2026
  • 3D Rendering of a Natural Killer Cell (NK Cell) destroying a cancer cell.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Artiva to quit autoimmune cell therapy work, cut staff after patient deaths

    The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.

    By • Oct. 27, 2026
  • Street signs for the intersection of Wall St. and Broad St., with the stripes of an American flag in the background.
    Image attribution tooltip
    Michael Santiago/Getty Images via Getty Images
    Image attribution tooltip
    Obesity drugs

    Corxel, an obesity drugmaker, to go public via SPAC deal

    Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets. 

    By • Oct. 26, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Another autoimmune CAR-T death; Treasury zeroes in on China deals

    A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.

    By • Oct. 26, 2026
  • A graphic deisgn of a lab process
    Image attribution tooltip
    Permission granted by Cytiva
    Image attribution tooltip
    Sponsored by Cytiva

    Novel protein and peptide therapeutics

    Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.

    Oct. 26, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: a big year for RNAi developers

    The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.

    By • Oct. 23, 2026
  • Space stars and nebula as purple abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Star adds $200M after spinout successes

    Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.

    By • Oct. 23, 2026
  • A street sign for Wall Street in front of the facade of the New York Stock Exchange.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Protein degrader specialist Lycia prices $318M IPO

    Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.

    By • Oct. 22, 2026
  • A horizontal headshot of Roivant Sciences chief executive officer Matt Gline.
    Image attribution tooltip
    Permission granted by Roivant Sciences
    Image attribution tooltip

    Roivant, continuing ascent, claims another victory for rare disease drug

    Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one analyst said.

    By Kristin Jensen • Oct. 21, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal

    New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.

    By • Oct. 21, 2026
  • Two people are seen through an open shelf of a laboratory, one person fills a cylinder with liquid.
    Image attribution tooltip
    Permission granted by Rapport Therapeutics
    Image attribution tooltip

    Rapport’s epilepsy drug finds surprising success in bipolar trial

    Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.

    By • Oct. 20, 2026
  • A financial graph on an abstract background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Disc’s once-spurned rare disease drug to get a second chance at approval

    Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

    By • Oct. 19, 2026
  • Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    Merck KGaA bets on RNAi with $1.3B Silence buyout

    The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

    By • Oct. 19, 2026
  • Speakers talking on stage at a conference
    Image attribution tooltip

    King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) / University Relations and Media Affairs

    Image attribution tooltip
    Sponsored by The Riyadh Global Medical Biotechnology Summit

    From strategy to scale: How Saudi Arabia is building a biotech ecosystem

    Saudi Arabia’s biotech strategy now has named partners, sites and capital behind it.

    Oct. 19, 2026
  • A picture of two Iambic Therapeutics executives smiling in front of the Nasdaq logo
    Image attribution tooltip
    Permission granted by 2026 Nasdaq, Inc. / Vanja Savic
    Image attribution tooltip
    Q&A // IPO window

    Iambic CEO on taking an AI drug company public

    Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.

    By • Oct. 16, 2026
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    This week in charts

    This week in charts: Moderna’s massive stock run

    The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

    By • Oct. 16, 2026